Avantor, Inc. (NYSE:AVTR) Shares Acquired by MetLife Investment Management LLC

MetLife Investment Management LLC increased its stake in shares of Avantor, Inc. (NYSE:AVTR) by 2,791.8% during the 3rd quarter, Holdings Channel reports. The fund owned 351,348 shares of the company’s stock after purchasing an additional 339,198 shares during the quarter. MetLife Investment Management LLC’s holdings in Avantor were worth $9,089,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors also recently bought and sold shares of AVTR. California State Teachers Retirement System lifted its stake in shares of Avantor by 0.5% in the 1st quarter. California State Teachers Retirement System now owns 1,067,938 shares of the company’s stock valued at $27,307,000 after purchasing an additional 5,230 shares during the period. Tidal Investments LLC raised its position in shares of Avantor by 19.6% in the first quarter. Tidal Investments LLC now owns 14,654 shares of the company’s stock worth $375,000 after acquiring an additional 2,399 shares during the period. Swedbank AB purchased a new stake in shares of Avantor during the 1st quarter worth about $2,707,000. Cetera Advisors LLC acquired a new stake in shares of Avantor during the 1st quarter valued at about $249,000. Finally, DekaBank Deutsche Girozentrale increased its stake in shares of Avantor by 146.7% in the 1st quarter. DekaBank Deutsche Girozentrale now owns 400,736 shares of the company’s stock valued at $10,205,000 after purchasing an additional 238,285 shares in the last quarter. 95.08% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Avantor

In other news, CAO Steven W. Eck sold 3,525 shares of the stock in a transaction on Thursday, September 5th. The stock was sold at an average price of $25.06, for a total transaction of $88,336.50. Following the completion of the transaction, the chief accounting officer now directly owns 29,544 shares in the company, valued at approximately $740,372.64. This represents a 10.66 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 1.30% of the stock is currently owned by company insiders.

Avantor Trading Up 0.1 %

Shares of AVTR stock opened at $21.04 on Friday. Avantor, Inc. has a twelve month low of $19.59 and a twelve month high of $28.00. The stock has a market cap of $14.32 billion, a price-to-earnings ratio of 45.74, a PEG ratio of 2.56 and a beta of 1.35. The company’s 50-day moving average price is $23.40 and its 200-day moving average price is $23.76. The company has a current ratio of 1.54, a quick ratio of 1.06 and a debt-to-equity ratio of 0.84.

Analysts Set New Price Targets

AVTR has been the subject of a number of recent analyst reports. Robert W. Baird cut their price objective on Avantor from $27.00 to $26.00 and set an “outperform” rating for the company in a research report on Monday, October 28th. Royal Bank of Canada reissued an “outperform” rating and issued a $34.00 price target on shares of Avantor in a report on Thursday, September 26th. Barclays decreased their price objective on shares of Avantor from $28.00 to $25.00 and set an “overweight” rating on the stock in a report on Friday, October 25th. UBS Group reduced their price target on shares of Avantor from $30.00 to $29.00 and set a “buy” rating for the company in a research report on Tuesday, October 8th. Finally, Wells Fargo & Company lowered their price objective on Avantor from $30.00 to $28.00 and set an “overweight” rating on the stock in a report on Monday, October 28th. Three equities research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. Based on data from MarketBeat, Avantor has an average rating of “Moderate Buy” and a consensus price target of $27.57.

Avantor Company Profile

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.